clinical trial · NCT06451913
Effect of Saccharomyces Boulardii CNCM I-745 on Gut Microbiota in Patients Undergoing Antibiotic Therapy (in the Context of Erythema Migrans (Early Skin Form of Lyme Borreliosis))
Erythema Migrans of Lyme DiseaseAmoxicillin + Saccharomyces boulardii CNCM I-745Amoxicillin + PlaceboStool samplesBSFS : Bristol Stool Form ScaleGSRS : Gastrointestinal Symptom Rating Scale
brief summary
The aim of this study is to assess the effect of Saccharomyces boulardii CNCM I-745 on gut microbiota in patients undergoing antibiotic therapy (in the context of erythema migrans (early skin form of Lyme borreliosis)).
started
Jul 16, 2025
primary completion
Dec 1, 2026
completion
Dec 1, 2026
last updated
Aug 27, 2025
detailed description
The study is designed to compare the efficacy of Saccharomyces boulardii CNCM-I-745 500 mg bid to a placebo in patients undergoing antibiotic therapy in the context of erythema migrans as the early form of Lyme borreliosis.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol